These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32156630)

  • 1. Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study.
    Taucher C; Barnett ED; Cramer JP; Eder-Lingelbach S; Jelinek T; Kadlecek V; Kiermayr S; Mills DJ; Pandis D; Reiner D; Dubischar KL
    Travel Med Infect Dis; 2020; 34():101616. PubMed ID: 32156630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO
    Jelinek T; Cromer MA; Cramer JP; Mills DJ; Lessans K; Gherardin AW; Barnett ED; Hagmann SHF; Askling HH; Kiermayr S; Kadlecek V; Eder-Lingelbach S; Taucher C; Dubischar KL
    Travel Med Infect Dis; 2018; 22():18-24. PubMed ID: 29549036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study.
    Taucher C; Kollaritsch H; Dubischar KL
    Vaccine; 2019 May; 37(19):2529-2531. PubMed ID: 30962094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.
    Kadlecek V; Borja-Tabora CF; Eder-Lingelbach S; Gatchalian S; Kiermayr S; Sablan B; Kundi M; Taucher C; Dubischar KL
    Pediatr Infect Dis J; 2018 Sep; 37(9):e233-e240. PubMed ID: 29912844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
    Dubischar KL; Kadlecek V; Sablan JB; Borja-Tabora CF; Gatchalian S; Eder-Lingelbach S; Kiermayr S; Spruth M; Westritschnig K
    Pediatr Infect Dis J; 2017 Sep; 36(9):898-904. PubMed ID: 28430748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
    Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
    Cramer JP; Dubischar K; Eder S; Burchard GD; Jelinek T; Jilma B; Kollaritsch H; Reisinger E; Westritschnig K
    Vaccine; 2016 Aug; 34(38):4579-4585. PubMed ID: 27460550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A; Bailleux F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.
    Erra EO; Askling HH; Rombo L; Riutta J; Vene S; Yoksan S; Lindquist L; Pakkanen SH; Huhtamo E; Vapalahti O; Kantele A
    Clin Infect Dis; 2012 Sep; 55(6):825-34. PubMed ID: 22696017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Product review on the JE vaccine IXIARO.
    Firbas C; Jilma B
    Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response at 12-23 months following a single dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
    Krow-Lucal ER; Laven J; Perry L; Biggerstaff BJ; Johnson BW; Hollis E; Fischer M; Woolpert T; Hills SL
    Vaccine; 2020 Oct; 38(44):6899-6903. PubMed ID: 32907756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.